Last reviewed · How we verify
LD Bris10 M2SR H3N2 influenza vaccine
LD Bris10 M2SR H3N2 influenza vaccine is a Biologic drug developed by FluGen Inc. It is currently in Phase 1 development.
At a glance
| Generic name | LD Bris10 M2SR H3N2 influenza vaccine |
|---|---|
| Sponsor | FluGen Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LD Bris10 M2SR H3N2 influenza vaccine CI brief — competitive landscape report
- LD Bris10 M2SR H3N2 influenza vaccine updates RSS · CI watch RSS
- FluGen Inc portfolio CI
Frequently asked questions about LD Bris10 M2SR H3N2 influenza vaccine
What is LD Bris10 M2SR H3N2 influenza vaccine?
LD Bris10 M2SR H3N2 influenza vaccine is a Biologic drug developed by FluGen Inc.
Who makes LD Bris10 M2SR H3N2 influenza vaccine?
LD Bris10 M2SR H3N2 influenza vaccine is developed by FluGen Inc (see full FluGen Inc pipeline at /company/flugen-inc).
What development phase is LD Bris10 M2SR H3N2 influenza vaccine in?
LD Bris10 M2SR H3N2 influenza vaccine is in Phase 1.
Related
- Manufacturer: FluGen Inc — full pipeline